- Cutting Jobless Will Take Time: White House's Summers
- GE, Vivendi Agree to Value NBCU Stake at $5.8 Billion
- Tuesday's ISM in Focus as Bulls Call for Turn in Dollar
- Arrest Imminent in Florida Ponzi Case: Report
- Cramer: Dubai Can’t Sink These 6 Dividend Stocks
- White House to Crank Up Pressure on Mortgage Industry
- Treasury Threatens Banks, Not Borrowers
- Good Sign for the Economy: 'Greed' Makes a Comeback
- The World's Biggest Debtor Nations
- Treasury Threatens Banks, Not Borrowers
- We're Approaching a Market Bubble: Portfolio Manager
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
- Cyber Monday: The Last Vestige of Dotcom Hype
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Dubai Stocks Could Fall a Further 30%: Charts
- Dubai World Set to Restructure About $26 Billion of Total Debt
- Good Sign for the Economy: 'Greed' Makes a Comeback
- Dubai Markets Open Sharply Lower for Second Day
- Should Homeowners Be Able To Walk Away From Mortgage?
- Bove: 26 Banks May Need To Raise More Capital
- Treasury Threatens Banks, Not Borrowers
- Nov. 30: Unusual Volume Leaders
- Notre Dame Fires Charlie Weis After 5 Seasons
Text Size 
Genentech reported earnings that edged forecasts on increased demand for its cancer drugs, but sales of all four of its big brand-name drugs, including Avastin, fell short of forecasts.
 |
AP The Genentech campus is seen in South San Francisco, Calif. |
The company was expected to earn 82 cents a share and see a 9 percent increase in sales to $3.113 billion, according to Thomson Financial.
Perhaps more importantly for investors, however, the company turned in sales figures for its biggest drugs that were short of forecasts.
Genentech sold $600 million worth of Avastin in the quarter, its most important cancer drug, compared with an expected $629 million.
"Genentech beat our earnings estimate, but Avastin sales were definitely light," said RBC Capital Markets analyst Jason Kantor.
"Everything else was fairly in line. So that's the news today, that Avastin was on the light side, and the stock trades very much on Avastin sentiment," Kantor said.
Among other major Genentech drugs, Rituxan sales reached $605 million, shy of the anticipated $607 million; Herceptin revenue was $339 million, compared with forecasts of $343 million, and Lucentis sales reached $198 million, compared with forecasts of $202 million.
Genentech shares were down about 1 percent in very choppy extended electronic trading. The stock [DNA
Loading...
()
] rose 0.37 percent to $78 during regular market hours Thursday.
"They don't get a gold star, but people were not expecting much out of this quarter ... People are looking for Avastin growth in breast cancer," said Analyst Mike King of Rodman & Renshaw, noting that FDA approval for that indication came too late in the quarter to have a major impact on sales.
On a non-adjusted basis, the world's second-largest biotechnology company posted a net profit of $790 million, or 74 cents per share, compared with a profit of $706 million, or 66 cents per share, a year earlier.
Shares of Genentech rose about 21 percent in the first quarter, closing at $81.18 March 31. The increase topped several broader indexes, which fell amid increasing concerns over the credit crisis and weakening economy.
- Reuters contributed to this report.
Print
Email
- Ever wished your cab driver would stop chatting and just get to where you're going? Well, that moment is closer than ever.
- UPS is giving its customers the option to offset its carbon emissions when sending a package.
- Romania's presidential campaign has been rocked by a video that may show the president striking a 10-year-old boy.
- Raising alligators is hard work, and the fickle taste of rich consumers has just made it much harder, says the NY Times.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- The continued real estate boom in China is partially fueled by a generational flood of newlyweds.
Data is a real-time snapshot *Data is delayed at least 15 minutes